686279-09-4

Usage

Uses

Used in Pharmaceutical Synthesis:
4,6-Dichloro-2-methyl-nicotinic acid ethyl ester is used as an intermediate in the pharmaceutical industry for the synthesis of various medicinal compounds. Its unique chemical structure allows for the development of drugs with specific therapeutic targets.
Used in Agrochemical Production:
In the agrochemical industry, 4,6-Dichloro-2-methyl-nicotinic acid ethyl ester serves as a key intermediate in the production of pesticides and other crop protection agents, contributing to the development of effective and targeted solutions for agricultural applications.
Used in Fine Chemicals Synthesis:
4,6-Dichloro-2-methyl-nicotinic acid ethyl ester is utilized in the synthesis of fine chemicals, which are high-purity chemicals used in various industries such as fragrances, flavors, and specialty chemicals. Its versatile chemical structure makes it a valuable component in creating complex and high-quality products.
Used in Research and Development:
4,6-Dichloro-2-methyl-nicotinic acid ethyl ester is employed in research and development settings to explore its potential applications and properties. Its unique structure and reactivity make it an interesting subject for scientific investigation, potentially leading to new discoveries and applications in various fields.
It is important to handle and store 4,6-Dichloro-2-methyl-nicotinic acid ethyl ester with care due to its potentially hazardous properties, ensuring safety in laboratories and industrial environments.

InChI:InChI=1S/C9H9Cl2NO2/c1-3-14-9(13)8-5(2)12-7(11)4-6(8)10/h4H,3H2,1-2H3

Upstream product

• 626-34-6 ethyl aminocrotonate 
• 626-34-6 ethyl 3-aminobut-2-enoate 
• 3950-10-5 5-Ethoxycarbonyl-4-hydroxy-6-methyl-pyridin-2(1H)-on 
• 3950-10-5 4,6-dihydroxy-2-methyl nicotinic acid ethyl ester 

Downstream Products

• 693285-72-2 4-chloro-6-(2,6-diethyl-phenyl)-2-methyl-nicotinic acid ethyl ester 
• 693286-31-6 4,6-dichloro-2-methylnicotinic acid 
• 1390657-41-6 tert-butyl 4-(4-((2-chloro-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390657-42-7 tert-butyl 4-(4-((2-((2,6-dichlorophenyl)amino)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390657-45-0 tert-butyl 4-(4-((2-(2,6-dichlorobenzyl)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390657-72-3 tert-butyl 4-(4-((2-(2-chlorophenoxy)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390656-09-3 2-(2-chlorophenoxy)-4-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[2,3-d]pyridazin-5(6H)-one 
• 1390657-77-8 tert-butyl 4-(4-((2-chloro-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxybenzyl)piperazine-1-carboxylate 
• 1390657-78-9 tert-butyl 4-(4-((2-(2-chlorobenzyl)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxybenzyl)piperazine-1-carboxylate 
• 1390656-12-8 2-(2-chlorobenzyl)-4-{[2-methoxy-4-(piperazin-1-ylmethyl)phenyl]amino}pyrido[2,3-d]pyridazin-5(6H)-one 
• 1390657-79-0 2-chloro-4-((2-methoxy-4-(morpholinomethyl)phenyl)amino)pyrido[2,3-d]pyridazin-5(6H)-one 
• 1390656-14-0 2-(2-chlorobenzyl)-4-{[2-methoxy-4-(morpholin-4-ylmethyl)phenyl]amino}pyrido[2,3-d]pyridazin-5-ol 
• 1390657-97-2 tert-butyl 4-(4-((2-chloro-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate 
• 1390657-98-3 tert-butyl 4-(4-((2-(2,6-dichlorobenzyl)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Used for the prevention and treatment of cardiovascular diseases

The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R1, R2, R3, X, Y, Z, A, B, G1, m, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R1, R2, R3, X, Y, Z, A, B, G1, m, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-iodopyridin-2(1H)-one type anti-HIV agents

A series of C-5 methyl substituted 4-arylthio- and 4-aryloxy-3-iodopyridin- 2(1H)-ones has been synthesized as new pyridinone analogues for their evaluation as anti-HIV inhibitors. The optimization at the 5-position was developed through an efficient use of the key intermediates 5-ethoxycarbonyl- and 5-cyano-pyridin-2(1H)-ones (14 and 15). Biological studies revealed that several compounds show potent HIV-1 reverse transcriptase inhibitory properties, for example, compounds 93 and 99 are active at 0.6-50 nM against wild type HIV-1 and a panel of major simple/double HIV mutant strains.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei? A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.